[Monoclonal antibodies against the factor VIII/Willebrand factor molecule: inhibition of the cofactor action of ristocetin and the antihemophilic factor].
Seven hybridoma cell lines secreting antibodies active against the F.VIII/vWF protein, were established. Three of them inhibit ristocetin-induced platelet aggregation, two others are directed against the antihemophilic activity and two bind to the molecule without any effect on biological activities.
D000818:Animals; D000906:Antibodies / Q000032:analysis*; D000911:Antibodies, Monoclonal; D000917:Antibody Formation; D001779:Blood Coagulation Factors / Q000276:immunology*; D002460:Cell Line; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D006822:Hybrid Cells; D051379:Mice; D008815:Mice, Inbred Strains; D012310:Ristocetin / Q000037:antagonists & inhibitors*; D014841:von Willebrand Factor / Q000276:immunology*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D001779:Blood Coagulation Factors; D014841:von Willebrand Factor; D012310:Ristocetin; D005169:Factor VIII
Anticorps monoclonaux dirigés contre la molécule de facteur VIII/facteur Willebrand: inhibition de l'activité cofacteur de la ristocétine et du facteur antihémophilique.